Cipla Launches Generic Liraglutide in US
MUMBAI, India & WARREN, N.J., USA – February 27, 2026 Cipla Limited announced the U.S. launch of Liraglutide Injection...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease solid tumors targeted therapy
MUMBAI, India & WARREN, N.J., USA – February 27, 2026 Cipla Limited announced the U.S. launch of Liraglutide Injection...
Hong Kong, January 26, 2026 — Ascletis Pharma continued progress in the clinical development of ASC30, its investigational oral...
Indianapolis, December 18, 2025 — Eli Lilly and Company announced positive topline results from its first-of-its-kind Phase 3 ATTAIN-MAINTAIN...
INDIANAPOLIS, December 11, 2025 — Eli Lilly and Company announced positive topline results from the Phase 3 TRIUMPH-4 trial,...
CAESAREA, Israel, Dec. 10, 2025 — Nitinotes Ltd., an early commercial-stage medical technology company developing fully automated endoluminal suturing...
BEIJING, China, Nov. 25, 2025 — Innovent Biologics and Eli Lilly announced that the supplementary application for Mazdutide 9mg...
BOSTON, October 29, 2025 — Wave Life Sciences Ltd. (NASDAQ: WVE), a clinical-stage biotechnology leader in RNA medicines, has...
Houston, Texas – September 23, 2025 — Eli Lilly and Company (NYSE: LLY) will invest $6.5 billion to build...
